New Delhi : Aurobindo Pharma on Wednesday posted a 4 per cent increase in its consolidated net profit to Rs 848 crore for the second quarter ended September 30, aided by robust sales in the US and Europe markets.The Hyderabad-based drug major had reported a net profit of Rs 817 crore in the July-September period of the last fiscal.

Aurobindo Pharma Q2FY26 Results: Strong Revenue Growth & Cash Position 💊📈 | MCap 66,850.27 Cr

- Revenue from Operations increased by 6.3% YoY to ₹8,286 Cr.

- US formulations revenue grew by 3.1% YoY to ₹3,638 Cr ($417M).

- Europe formulations revenue rose 17.8% YoY to… pic.twitter.com/gfJVzAoXdx — Investor Feed (@_Investor_Feed_) November 5, 2025

Its revenue from operations rose to Rs 8,286 crore for the September quarter from Rs 7,796 crore in the ye

See Full Page